Radnostix, Inc. (INIS), a radiopharmaceutical firm, announced the completion of its purchase of Lucerno Dynamics, LLC’s LARA System technology platform, ELLEXA Explorer software, and related intellectual property.
While the financial details of the transaction were not disclosed, the acquisition enables Radnostix to develop new radiopharmaceutical and nuclear medicine products, with a focus on drug delivery and real‑time monitoring.
Shahe Bagerdjian, CEO of Radnostix, said the acquisition will strengthen the company’s medical device portfolio and support the development of solutions for radioligand therapy administration clinics.
INIS closed at $0.07 in OTC Markets trading on Tuesday.
Also Read
- Pakistan’s President Zardari to Visit Kyrgyzstan for High-Level Talks on Trade and Energy Cooperation]
- Israeli command system identified 850,000 targets in Gaza and Lebanon wars, says supplier
- Africa News Brief: Sudan Drone Crisis, Nigeria Hunger Alert, and Regional Tensions[TITLE]
- Trump attacks Meloni before Nato summit in Ankara: ‘Needs a restraining order’

